Plus Therapeutics Files Proxy Materials
Ticker: PSTV · Form: DEFA14A · Filed: Aug 1, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | DEFA14A |
| Filed Date | Aug 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-actions
TL;DR
PLUS proxy materials filed, shareholder votes coming up.
AI Summary
Plus Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on August 1, 2025. The filing relates to the company's proxy materials, which are subject to SEC rules. The company's former names include Cytori Therapeutics, Inc. and Macropore Inc.
Why It Matters
This filing indicates that Plus Therapeutics is proceeding with corporate actions requiring shareholder approval, as outlined in their proxy statement.
Risk Assessment
Risk Level: low — This is a routine SEC filing for proxy materials and does not inherently present new risks.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- CYTORI THERAPEUTICS, INC. (company) — Former company name
- MACROPORE INC (company) — Former company name
- August 1, 2025 (date) — Filing date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is PLUS THERAPEUTICS, INC.
When was this filing made?
The filing was made on August 1, 2025.
What are some previous names of the company?
The company was formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC.
What is the company's business address?
The business address is 4200 MARATHON BLVD., SUITE 200, AUSTIN, TX 78756.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on August 1, 2025 regarding PLUS THERAPEUTICS, INC. (PSTV).